Jishi Medical Completes Pre-A Financing Round Led by Fojian Capital

Investment Circle (ID: pedaily2012) November 8th, by Arterial Network report, Focusight has recently completedPre-A round of financing exclusively invested by Rehealth Capital.With the successful injection of this round of funding, Focusight will significantly increase its production capacity, continuously consolidate and expand its amblyopia treatment solutions for all age groups, steadily advance the commercialization process of its approved products, and accelerate the launch of products in its pipeline for strabismus, glaucoma, and presbyopia.

Focusight, established in 2020, is a globally leading ophthalmic diagnosis and treatment platform driven by brain science mechanism research. The company focuses on industry-academia-research collaboration to break through the limitations of traditional intervention methods in terms of age, effectiveness, location, and compliance by leveraging "fundamental brain science + eye disease mechanism research + wearable intelligent products," improving intervention outcomes and accessibility for patients with eye conditions. Currently, the company's products have covered the needs of patients with amblyopia, myopia, dry eye, and end-stage eye diseases, and have formed multiple proprietary intellectual properties across various ophthalmic treatment fields.

On October 25, 2024, Focusight reached an important milestone — its treatment product designed for children with amblyopia was the first to receive the Class II Medical Device Product Registration Certificate issued by the Zhejiang Provincial Drug Administration.

At the same time, Focusight is also expanding its innovative product portfolio in depth. Relying on the world's leading ophthalmic diagnosis and treatment solutions driven by brain cognition, the company continues to develop wearable device-based, clinically aligned, personalized, and highly compliant therapeutic products. While strengthening its layout in traditional areas of advantage, Focusight enriches its innovative product pipeline, creating an eye disease treatment ecosystem that aims to provide patients with comprehensive, full-lifecycle ophthalmic health management solutions.

Focusight has established in-depth industry-university-research cooperation with top ophthalmology platforms in China, such as the Eye, Ear, Nose and Throat Hospital of Fudan University, the Eye Hospital of Wenzhou Medical University, and the Zhongshan Ophthalmic Center of Sun Yat-sen University, committing to provide patients with more precise and effective treatment solutions.